Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll RP105-negative B cells in systemic lupus erythematosus Koarada S; Tada YClin Dev Immunol 2012[]; 2012 (ä): 259186Systemic lupus erythematosus (SLE) is a multisystem disease characterized by B cells producing autoantibodies against nuclear proteins and DNA, especially anti-double-strand DNA (dsDNA) antibodies. RP105 (CD180), the toll-like receptor- (TLR-) associated molecule, is expressed on normal B cells. However, RP105-negative B cells increase in peripheral blood from patients with active SLE. RP105 may regulate B-cell activation, and RP105-negative B cells produce autoantibodies and take part in pathophysiology of SLE. It is possible that targeting RP105-negative B cells is one of the treatments of SLE. In this paper, we discuss the RP105 biology and clinical significance in SLE.|Animals[MESH]|Antibodies, Monoclonal, Murine-Derived/therapeutic use[MESH]|Antigens, CD/*analysis/physiology[MESH]|Autoantibodies/biosynthesis/immunology[MESH]|B-Lymphocyte Subsets/*immunology[MESH]|Disease Models, Animal[MESH]|Humans[MESH]|Immunophenotyping[MESH]|Immunotherapy/methods[MESH]|Lupus Erythematosus, Systemic/*immunology[MESH]|Lymphocyte Activation[MESH]|Mice[MESH]|Rheumatic Diseases/immunology[MESH]|Rituximab[MESH]|Toll-Like Receptors/immunology[MESH] |